[시장보고서]mRNA 합성 및 제조 시장 : 업계 동향과 세계 예측(-2035년) - 제품별, 사업 규모별, 합성·제조 활동별, 적응증 유형별, 치료 영역별, 용도별, 지역별

mRNA 합성 및 제조 시장 : 업계 동향과 세계 예측(-2035년) - 제품별, 사업 규모별, 합성·제조 활동별, 적응증 유형별, 치료 영역별, 용도별, 지역별

mRNA Synthesis and Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Product, Scale of Operation, Synthesis and Manufacturing Activity, Indication Type, Therapeutic Area, Application Area and Geographical Regions

상품코드 : 1869572

리서치사 : Roots Analysis

발행일 : 2025년 10월

페이지 정보 : 영문 341 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,799

￦ 7,105,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999

￦ 10,363,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599

￦ 15,693,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999

￦ 26,651,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

mRNA 합성·제조 시장 : 개요

Roots의 분석에 따르면 mRNA 합성·제조 시장 규모는 2028-2035년에 20%의 CAGR로 확대하며, 현재 11억 5,000만 달러에서 2035년까지 13억 5,000만 달러로 성장할 것으로 예측됩니다.

mRNA 합성 및 제조 시장

시장 규모 및 기회 분석은 다음 매개 변수를 기반으로 세분화됩니다.

제품 유형

의약품 유효성분
완성된 제형

사업 규모

전임상 및 임상 규모
상업적 규모

합성 및 제조 활동

수탁제조
자체 제조

적응증 유형

COVID 관련 적응증
비 COVID 적응증

치료 영역

감염성 질환
종양학 영역
기타

용도

mRNA 백신
mRNA 치료제

지역

북미
유럽
아시아태평양
라틴아메리카
중동 및 북아프리카

mRNA 합성 및 제조 시장 : 성장과 동향

리보핵산(RNA)은 모든 생물의 세포 내에 존재하는 분자로, 유전정보를 다양한 단백질로 변환하여 세포의 다양한 기능을 담당하고 있습니다. 중요한 점은 RNA는 메신저 RNA(mRNA), 전사 RNA(tRNA), 리보솜 RNA(rRNA) 등 다양한 형태로 존재한다는 점입니다. 이 중 mRNA는 현대 의료 산업에서 매우 중요한 치료 접근법이 되고 있습니다.

mRNA는 DNA에 존재하는 유전정보를 단백질 합성에 전달하는 단일가닥 RNA 분자입니다. mRNA의 유전정보는 아미노산으로 번역되고, 이후 기능적 산물(단백질)로 가공됩니다. 특히 COVID-19 팬데믹 이후 mRNA 백신 및 치료제 생산은 COVID-19 감염증을 치료할 수 있는 차세대 의약품으로 주목받고 있습니다. 또한 mRNA 치료는 다양한 종양성 질환, 감염성 질환, 유전성 질환의 관리에서도 평가가 진행되고 있습니다. 이러한 다양성과 확장성으로 인해 mRNA 치료제의 채택이 확대되고 있으며, 개인 맞춤형 mRNA 의료 생산 및 백신 개발의 기반이 되고 있습니다. 또한 삽입 돌연변이 유발 위험이 낮기 때문에 환자의 안전성 프로파일이 개선될 것으로 기대됩니다.

이러한 성공으로 mRNA 합성 및 생산에 대한 수요가 크게 증가하여, mRNA 치료제/백신 개발 기업은 현재 수요를 충족시킬 수 있는 대안을 적극적으로 모색하고 있습니다. 이러한 점에서 mRNA 치료제/백신 개발 기업에게 아웃소싱은 수익성 높은 선택이 될 수 있으며, mRNA 치료제 및 백신 개발을 위한 효과적이고 확장성 있는 솔루션을 제공합니다. mRNA 합성 및 제조 분야의 현재 동향과 예상되는 기회를 고려할 때, 이 분야는 가까운 미래에 한 자릿수 시장 성장이 예상됩니다.

mRNA 합성 및 제조 시장 : 주요 연구 결과

이 보고서는 mRNA 합성 및 제조 시장의 현황을 상세하게 분석하고 업계의 잠재적인 성장 기회를 파악합니다. 주요 조사 결과는 다음과 같습니다.

현재 시장 상황에서는 전 세계에서 약 55개 업체가 mRNA 합성 맞춤형 서비스를 제공한다고 주장하고 있으며, 그 중 60%가 북미에 본사를 두고 있습니다.

mRNA Synthesis and Manufacturing Market-IMG1

2. mRNA 맞춤 합성 서비스 제공 기업의 대부분(약 95%)은 mRNA의 5'말단 변형 서비스를 제공합니다. 이는 주로 mRNA의 안정성과 번역 효율 향상, 면역원성 위험 감소에 기여하기 위함입니다.

3. 이해관계자들은 자사의 제품 포트폴리오를 강화하고, mRNA 맞춤 합성 분야에서 활동하는 타사 대비 경쟁 우위를 확보하기 위해 기존 역량을 적극적으로 향상시키고 있습니다.

4. mRNA 백신 수요 증가와 mRNA 합성 및 제조 기술 발전에 따라 약 45개 업체가 mRNA 수탁제조 서비스를 활발히 제공합니다.

5. 약 60%의 기업이 원약과 제제 모두에 대한 mRNA 수탁제조 서비스를 제공하고 있으며, 약 90%의 사업자가 임상규모의 mRNA 수탁제조 서비스를 제공합니다.

6. mRNA 수탁제조 서비스 프로바이더는 서비스 포트폴리오 강화와 경쟁력 있는 시장 기반 구축을 위해 mRNA 제조 역량을 적극적으로 확대 및 다각화를 추진하고 있습니다.

7. 현재 약 115종의 mRNA 합성용 키트가 시장에 유통되고 있으며, 분자생물학, 단백질 생산, 백신 개발 등 다양한 용도에 대응할 수 있도록 설계되어 있습니다.

8. mRNA 합성 키트는 고객의 특정 요구를 충족시키기 위해 다양한 구성 요소로 구성되어 있습니다. 특히 T7 중합효소는 95% 이상의 mRNA 합성 키트에서 제공되는 가장 선호되는 효소 유형으로 부상하고 있습니다.

9. 현재 mRNA 합성을 위한 키트는 약 115유형이 시중에 유통되고 있습니다. 이 키트는 분자생물학, 단백질 생산, 백신 개발 등 다양한 용도로 사용할 수 있도록 설계되었습니다.

10. mRNA 합성 키트는 고객의 특정 요구를 충족시키기 위해 다양한 구성 요소로 구성되어 있습니다. 특히 T7 중합효소는 95% 이상의 mRNA 합성 키트에서 제공되는 가장 선호되는 효소 유형으로 부상하고 있습니다.

11. 이 시장에 대한 관심 증가는 최근 수년간 다양한 이해관계자들 사이에 맺어진 다양한 제휴 관계에도 반영되어 있습니다. 실제로 지난 3년간 약 50%의 거래가 체결되었습니다.

12. 전 세계의 다양한 mRNA 기반 치료제/백신 개발 기업은 자사의 의약품 포트폴리오를 더욱 확대하기 위해 mRNA 합성 및 제조 서비스 프로바이더와 전략적 제휴를 맺을 것으로 예측됩니다.

13. 이 분야의 주요 제약사 활동의 대부분(약 30%)은 사노피가 주도하고 있으며, 그 중 대부분(50%)은 이 분야에서 활동하는 다양한 이해관계자와의 제휴 및 공동연구 사례로 나타났습니다.

14. 현재 mRNA 합성 및 제조 시장 점유율의 대부분은 북미가 차지하고 있습니다. 이는 첨단화된 의료 인프라가 구축되어 있고, 관련 기업이 광범위한 조사를 수행할 수 있는 환경이 조성되어 있기 때문인 것으로 보입니다.

15. mRNA 치료제 및 백신이 해당 질환의 치료에 효과적이기 때문에 감염성 질환 하위 부문은 올해 전체 시장의 대부분을 차지할 것으로 예측됩니다.

mRNA Synthesis and Manufacturing Market-IMG2

16. 북미는 전체 mRNA 합성 및 제조 시장에서 중요한 점유율을 차지할 것으로 예상되며, 이러한 추세는 앞으로도 변하지 않을 것으로 예측됩니다.

17. 미국내 주요 기업별 mRNA 기반 백신 및 치료제의 빠른 성공에 힘입어 mRNA 합성 및 제조 시장은 연평균 6.5%의 성장률을 보일 것으로 예측됩니다.

mRNA 합성 및 제조 시장 : 주요 부문

의약품 원료의약품이 mRNA 합성 및 제조 시장에서 가장 큰 점유율을 차지합니다.

당사의 추정에 따르면 올해에는 mRNA 합성 및 제조 시장 점유율의 대부분(60% 이상)을 원료의약품 하위 부문이 차지할 것으로 예측됩니다. 이는 원료의약품이 모든 치료제/백신의 기본 성분이며, 제품의 전반적인 효능과 안전성에 영향을 미친다는 사실에 기인합니다.

상업적 규모가 mRNA 합성 및 제조 시장에서 가장 큰 점유율을 차지합니다.

올해 상업적 규모의 하위 부문은 다수의 mRNA 기반 치료제 및 백신의 상용화로 인해 가장 높은 점유율(85% 이상)을 차지했습니다. 또한 전임상 및 임상 규모 시장은 예측 기간 중 완만한 증가가 예상됩니다. 이 분야의 중요한 연구개발은 전임상 및 임상 영역의 성장을 가속하고 있으며, mRNA 기반 제품 개발 증가로 이어지고 있습니다. 또한 각 업체들은 각기 다른 규모의 운영 강화를 위해 mRNA 생산 시설 확충에 주력하고 있습니다.

mRNA 합성 및 제조 시장에서는 수탁제조이 지배적일 것으로 전망

올해 수탁제조 하위 부문이 가장 큰 시장 점유율(약 60%)을 차지했습니다. 이러한 장점은 주로 전문적인 노하우가 필요하고 종종 제3의 서비스 프로바이더에 의존하는 mRNA 생산의 복잡성에서 기인합니다. 또한 예측 기간 중 사내 제조 하위 부문의 점유율이 크게 증가하여 CAGR 7.5%를 보일 것으로 예측됩니다.

비 COVID 적응증은 예측 기간 중 눈에 띄는 CAGR로 성장할 것으로 예측됩니다.

COVID19 관련 적응증 하위 부문은 올해 가장 큰 시장 점유율(95%)을 차지하고 있습니다. 이는 mRNA 기반 제품이 세포에 특정 병원체 단백질을 생산하도록 지시하여 실제 병원체에 노출되지 않고도 강력하고 표적화된 면역 반응을 유발할 수 있기 때문입니다. 또한 비 COVID-19 적응증에 대한 시장 점유율이 크게 증가하여 예측 기간 중 37.5%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

감염성 질환을 위한 mRNA 치료에 대한 관심

올해 감염성 질환 하위 부문이 가장 큰 시장 점유율(약 95%)을 차지했습니다. 이는 mRNA 치료제와 백신이 COVID-19 팬데믹 대응에 있으며, 매우 높은 성공을 거둔 사실에 기인합니다. 또한 암 질환 증가 추세와 종양학 질환을 효율적으로 치료하기 위한 새로운 치료법 개발의 필요성으로 인해 종양학 분야에서도 괄목할 만한 시장 성장이 예상됩니다.

mRNA 백신은 mRNA 합성 및 제조 시장에서 가장 큰 점유율을 차지합니다.

mRNA 합성 및 제조 시장 예측에 따르면 올해 mRNA 백신 하위 부문이 시장을 주도하고 있습니다. 그 배경에는 확실한 임상적 성공, 광범위한 예방적 적용 가능성, 유연한 특성이 있습니다. 또한 mRNA 치료제의 점유율은 예측 기간 중 CAGR 61.1%로 성장하여 큰 폭으로 증가할 것으로 예측됩니다. 이는 종양학, 유전질환, 자가면역질환, 심혈관질환 등의 치료 영역에서 치료용도가 빠르게 확대되고 있으며, mRNA 치료제에 대한 강력한 임상적 모멘텀을 창출하고 있기 때문입니다.

향후 수년간 북미가 mRNA 합성 및 제조 분야를 주도할 것입니다.

북미가 시장의 대부분(40% 이상)을 차지할 것으로 예측됩니다. 또한 북미 시장은 예측 기간 중 6.6%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이는 북미의 첨단화된 의료 인프라를 통해 여러 업계 기업이 광범위한 조사를 수행하고 다양한 치료 적응증에 대한 새로운 mRNA 양식을 개발할 수 있기 때문입니다.

mRNA 합성 및 제조 시장의 대표적인 진출 기업 사례

Aldevron
APExBIO
Aurigene Pharmaceutical Services
BioCell
Biomay
BioNTech
Biorbyt
CELLSCRIPT
Creative Biogene
Curia
Eurogentec
GenScript
eJena Bioscience
Lonza
Merck
Porton Advanced
Revolution Biotechnology
Samsung Biologics
ST Pharm
Thermo Fisher Scientific
TriLink BioTechnologies
Vernal Biosciences
WuXi Biologics
YXgene

mRNA 합성·제조 시장 : 파트너 후보 분석
조사 방법과 주요 파라미터
채점 기준
mRNA 의약품 개발 기업 : 북미에 본사를 둔 파트너 후보
mRNA 의약품 개발 기업 : 유럽에 본사를 둔 파트너 후보
mRNA 의약품 개발자 : 아시아태평양 및 기타 지역에 기반을 둔 파트너 후보

제18장 대기업 구상

조사 방법
주요 구상의 분석
mRNA 합성·제조 시장 : 대기업 구상

제19장 시장 영향 분석

시장 촉진요인
시장 억제요인
시장의 기회
시장이 해결해야 할 과제

제20장 세계의 mRNA 합성·제조 시장

제21장 mRNA 합성·제조 시장(제품 유형별)

제22장 mRNA 합성·제조 시장(사업 규모별)

제23장 mRNA 합성·제조 시장(합성·제조 활동별)

제24장 mRNA 합성·제조 시장(적응증 유형별)

제25장 mRNA 합성·제조 시장(치료 영역별)

제26장 mRNA 합성·제조 시장(용도별)

제27장 mRNA 합성·제조 시장(지역별)

제28장 시장 기회 분석 : 북미

제29장 시장 기회 분석 : 유럽

제30장 시장 기회 분석 : 아시아태평양

제31장 시장 기회 분석 : 라틴아메리카

제32장 시장 기회 분석 : 중동·북아프리카

제33장 결론

제34장 이그제큐티브 인사이트

제35장 부록 I : 표 데이터

제36장 부록 II : 기업 및 조직 리스트

KSA

영문 목차

영문목차

MRNA SYNTHESIS AND MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the mRNA synthesis and manufacturing market is estimated to grow from USD 1.15 billion in the current year to USD 1.35 billion by 2035, at a CAGR of 20% between 2028 and 2035.

mRNA Synthesis and Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Product

Active Pharmaceutical Ingredients
Finished Dose Formulations

Scale of Operation

Preclinical and Clinical Scale
Commercial Scale

Synthesis and Manufacturing Activity

Contract Manufacturing
In-house Manufacturing

Indication Type

COVID Indications
Non-COVID Indications

Therapeutic Area

Infectious Diseases
Oncological Disorders
Other Disorders

Application Area

mRNA Vaccines
mRNA Therapeutics

Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Middle East and North Africa

MRNA SYNTHESIS AND MANUFACTURING MARKET: GROWTH AND TRENDS

Ribonucleic acid (RNA) is a molecule found in all living cells that translates genetic information into different proteins to carry out various cellular functions. Importantly, RNA can exist in various forms, such as messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). Amongst these, mRNA has become a crucial therapeutic approach in modern healthcare industry.

mRNA is a single-stranded RNA molecule that carries the genetic information found in DNA to synthesize proteins. The genetic information found on mRNA is translated into amino acids, which are then processed into a functional product (proteins). Significantly, following the COVID-19 pandemic, the production of mRNA vaccines and therapeutics has attracted notable focus as they have developed into a next-generation class of drugs for treating the COVID-19 infection. Additionally, mRNA therapies are being assessed for the management of different oncological, infectious, and genetic conditions. This versatility and scalability of mRNA therapeutics have further contributed to their adoption, positioning them as a cornerstone of personalized mRNA medicine production and vaccine development. Moreover, these therapies are expected to possess enhanced safety profiles for patients due to the low risk of insertional mutagenesis.

Due to this success, the need for mRNA synthesis and production has risen significantly, leading mRNA therapeutic /vaccine developers to actively investigate alternatives to meet the current demand. In this regard, outsourcing became a profitable choice for companies involved in mRNA therapeutic / vaccine development, providing effective and scalable solutions for mRNA therapeutics and vaccine development. Given the current trends and anticipated opportunities in the mRNA synthesis and manufacturing sector, we anticipate that this field is poised for single-digit market growth in the near future.

mRNA SYNTHESIS AND MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the mRNA synthesis and manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

1. The current market landscape features the presence of close to 55 providers that claim to offer customized services for mRNA synthesis across the world; 60% of these are headquartered in North America.

2. Majority (~95%) of the mRNA custom synthesis service providers offer 5' modifications of mRNA, primarily because it enhances mRNA stability, translation efficiency and reduces chances of immunogenicity.

3. Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the mRNA custom synthesis domain.

4. Owing to the rising demand for mRNA vaccines coupled with advancements in mRNA synthesis and manufacturing technologies, ~45 companies are actively offering mRNA contract manufacturing services.

5. Around 60% of the companies are offering mRNA contract manufacturing services for both drug substances and drug products; ~90% players offer mRNA contract manufacturing services at clinical scale.

6. mRNA contract manufacturing service providers are proactively enhancing and diversifying their mRNA manufacturing capabilities to strengthen their service portfolios and establish a competitive market foothold.

7. Presently, close to 115 kits are available in the market for mRNA synthesis; these kits are designed to cater to a wide range of applications, including molecular biology, protein production and vaccine development.

8. mRNA synthesis kits comprise of a variety of components, catering to the specific needs of clients; notably, T7 polymerase emerged as the most preferred type of enzyme being offered in more than 95% mRNA synthesis kits.

9. Presently, close to 115 kits are available in the market for mRNA synthesis; these kits are designed to cater to a wide range of applications, including molecular biology, protein production and vaccine development.

10. mRNA synthesis kits comprise of a variety of components, catering to the specific needs of clients; notably, T7 polymerase emerged as the most preferred type of enzyme being offered in more than 95% mRNA synthesis kits.

11. The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, close to 50% of the deals were inked in the last three years.

12. Various mRNA-based therapeutic / vaccine developers across the world are anticipated to forge strategic alliances with mRNA synthesis and manufacturing service providers to further augment their drug portfolio.

13. Majority (~30%) of the big pharma activities in this domain have been led by Sanofi; of these, most of the initiatives (50%) were instances of partnerships and collaborations inked with various stakeholders active in this domain.

14. Currently, majority of the mRNA synthesis and manufacturing market share is captured by North America; this can be attributed to the advanced healthcare infrastructure, enabling players to conduct extensive research.

15. The infectious diseases sub-segment is estimated to capture most of the overall market share in the current year, owing to the effectiveness of mRNA therapeutics and vaccines in the treatment of such diseases.

16. North America is expected to capture a significant market share of the overall mRNA synthesis and manufacturing market; this trend is unlikely to change in the future.

17. Driven by the rapid success of mRNA-based vaccines and therapeutics developed by prominent players in the US, the mRNA synthesis and manufacturing market is expected to grow at CAGR of 6.5%.

mRNA SYNTHESIS AND MANUFACTURING MARKET: KEY SEGMENTS

Active Pharmaceutical Ingredients Holds the Largest mRNA Synthesis and Manufacturing Market Share

Our estimates suggest that in the current year, the active pharmaceutical ingredients sub-segment is likely to capture majority (>60%) of the mRNA synthesis and manufacturing market share. This can be attributed to the fact that active pharmaceutical ingredients are a fundamental component of any therapeutic / vaccine, that impact the overall efficacy and safety of the product.

Commercial Scale Captures the Largest mRNA Synthesis and Manufacturing Market Share

In the current year, commercial scale sub-segment captures the highest market share (>85%), owing to the commercialization of a large number of mRNA-based therapeutics and vaccines. Further, the market for preclinical and clinical scale is likely to witness a moderate increase during the forecast period. Significant research and development in this field are driving growth in the preclinical and clinical areas, resulting in a rise in the development of mRNA-based products. Additionally, the firms are concentrating on expanding mRNA production facilities to enhance operations at different scales.

Contract Manufacturing is Anticipated to Dominate the mRNA Synthesis and Manufacturing Market

In the current year, the contract manufacturing sub-segment occupies the highest market share (~60%). This dominance is primarily driven by the complexity of mRNA production, which demands specialized expertise and often relies on third-party service providers. Further, the market is likely to witness a substantial increase in the share of in-house manufacturing sub-segment, growing at a CAGR of 7.5% during the forecast period.

Non-COVID-Indications is Likely to Grow at a Notable CAGR During the Forecast Period

The COVID indication sub-segment occupies the highest market share (95%) in the current year. This can be attributed to the fact that mRNA-based products can instruct cells to produce specific pathogen proteins, which in turn trigger a strong and targeted immune response without exposing the individual to the actual pathogen. Further, the market is likely to witness a substantial increase in the share of non-COVID indications, growing at a CAGR of 37.5% during the forecast period.

Focus on Infectious Disease mRNA Therapies

In the current year, the infectious diseases sub-segment occupies the highest market share (~95%), given the fact that mRNA therapeutics and vaccines demonstrated tremendous success in combating the COVID-19 pandemic. Further, the oncology segment is likely to witness significant market growth owing to the increasing prevalence of cancer and the need to develop novel therapeutic options to treat oncological disorders efficiently.

mRNA Vaccines Holds the Largest mRNA Synthesis and Manufacturing Market Share

In the current year, the market is solely driven by mRNA vaccines sub-segment as per mRNA synthesis and manufacturing market forecast, given their proven clinical success, broad preventive applications and flexible nature. Further, the market is likely to witness a substantial increase in the share of mRNA therapeutics, growing at a CAGR of 61.1% during the forecast period. This is because of their rapidly expanding therapeutic applications for therapeutic areas such as oncological, genetic, autoimmune and cardiovascular disorders, thus generating a strong clinical momentum for mRNA therapeutics.

North America to Propel in the mRNA Synthesis and Manufacturing Sector in the Coming Years

North America is likely to capture majority share (>40%) of the market. In addition, the market in North America is expected to grow at a CAGR of 6.6%, during the forecast period. This is because of the advanced healthcare infrastructure in North America, enabling several players in the industry to conduct extensive research and develop novel mRNA modalities for a wide array of therapeutic indications.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

Chief Executive Officer, Mid-sized Organization, Belgium
Chief Commercial Officer, Mid-sized Organization, France
Business Development Manager, Mid-sized Organization, Spain
Team Leader, Large Organization, South Korea

In addition, the market report includes transcripts of the following other third-party discussions:

Scientist in Nucleic Acid Therapeutics, Very Large Organization, United States
Senior Product Manager, Very Large Organization, United States
NEB RNA Research Senior Scientist, Large Organization, United States
Professor and Director of the BASE facility and, Associate Professor and Deputy Director of the BASE facility, Vert Large Organization, Australia

Example Players in the mRNA Synthesis and Manufacturing Market

Aldevron
APExBIO
Aurigene Pharmaceutical Services
BioCell
Biomay
BioNTech
Biorbyt
CELLSCRIPT
Creative Biogene
Curia
Eurogentec
GenScript
eJena Bioscience
Lonza
Merck
Porton Advanced
Revolution Biotechnology
Samsung Biologics
ST Pharm
Thermo Fisher Scientific
TriLink BioTechnologies
Vernal Biosciences
WuXi Biologics
YXgene

mRNA SYNTHESIS AND MANUFACTURING MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA synthesis and manufacturing market, focusing on key market segments, including [A] type of product, [B] scale of operation, [C] synthesis and manufacturing activity, [D] indication type, [E] therapeutic area, [F] application area and [G] geographical regions.
Market Landscape 1: A detailed assessment of companies offering mRNA custom synthesis services, based on several relevant parameters, including [A] year of establishment, [B] company size, [C] location of the headquarters, [D] type of service offered, [E] type of starting material, [F] structural modification, [G] type of purification method, [H] scale of operation, [I] application area and [J] GMP compliance.
Company Competitiveness Analysis: A competitiveness analysis of mRNA custom synthesis service providers, based on [A] supplier strength, and [A] service strength
Market Landscape 2: A comprehensive assessment of the mRNA contract manufacturing service providers, based on [A] year of establishment, [B] company size, [C] location of the headquarters, [D] location of manufacturing facilities, [E] type of product, [F] type of additional services offered, [G] scale of operation, [H] GMP compliance.
Company Competitiveness Analysis: In-depth company competitiveness analysis of mRNA contract manufacturing service providers based on [A] supplier strength and [B] service strength.
Market Landscape 3: A detailed assessment of the current market landscape of mRNA synthesis kits based on several relevant parameters, such as [A] kit, [B] type of enzyme, [C] type of enzyme mix used, [D] type of mRNA component modified, [E] number of reactions, [F] yield per reaction, [G] reaction run-time and shelf life, [H] year of establishment, [I] company size, [J] location of the headquarters and [K] most active players.
Product Competitive Analysis: An insightful analysis of mRNA synthesis kits, based on [A] developer strength and [B] product portfolio strength.
Company Profiles: In-depth profiles of prominent players across North America, Europe and Asia-Pacific, focusing on [A] year of establishment, [B] location of headquarters, [C] B-mRNA synthesis service portfolio, [D] recent developments and [E] an informed future outlook.
Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders engaged in this industry, based on several parameters, such as [A] year of partnership, [A] type of partnership, [B] type of product, [C] type of partner and [D] most active players.
Likely Partner Analysis: a comprehensive analysis of mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers.
Big Pharma Initiatives: A review of the various mRNA-focused initiatives undertaken by big players, highlighting trends across various parameters, such as [A] number of initiatives, [A] year of initiative, [A] type of partnership, [B] type of expansion, [C] region of expansion, [D] type of pharmaceutical and [E] therapeutic area.
Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the mRNA synthesis and manufacturing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global capacity of developers?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Overview of mRNA
6.2. Structure of mRNA
6.3. Evolution of mRNA Vaccines
6.4. Types of mRNA Synthesis Processes
- 6.4.1. Chemical Synthesis of mRNA
- 6.4.2. In vitro Synthesis of mRNA
6.5. Applications of mRNA
6.6. Challenges Associated with mRNA Synthesis
6.7. Commonly Outsourced mRNA Manufacturing Operations
6.8. Advantages of Outsourcing Manufacturing Operations
6.9. Conclusion

7. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: MARKET LANDSCAPE

7.1. Overview of mRNA Custom Synthesis Service Providers
- 7.1.1. Analysis by Year of Establishment
- 7.1.2. Analysis by Company Size
- 7.1.3. Analysis by Location of Headquarters
- 7.1.4. Analysis by Company Size and Location of Headquarters
- 7.1.5. Analysis by Type of Service Offered
- 7.1.6. Analysis by Type of Starting Material
- 7.1.7. Analysis by Structural Modification
- 7.1.8. Analysis by Type of Purification Method
- 7.1.9. Analysis by Scale of Operation
- 7.1.10. Analysis by Application Area
- 7.1.11. Analysis by GMP Compliance

8. COMPANY COMPETITIVENESS ANALYSIS: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

8.1. Methodology and Key Parameters
8.2. Scoring Criteria
8.3. Overview of Peer Groups
8.4. Company Competitiveness Analysis
- 8.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
- 8.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
- 8.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
- 8.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
- 8.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
- 8.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

9. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE

9.1. Overview of mRNA Contract Manufacturing Service Providers
- 9.1.1. Analysis by Year of Establishment
- 9.1.2. Analysis by Company Size
- 9.1.3. Analysis by Location of Headquarters (Region)
- 9.1.4. Analysis by Location of Headquarters (Country)
- 9.1.5. Analysis by Location of Manufacturing Facilities
- 9.1.6. Analysis by Type of Product Manufactured
- 9.1.7. Analysis by GMP Compliance
- 9.1.8. Analysis by Scale of Operation
- 9.1.9. Analysis by Type of Additional Services Offered

10. COMPANY COMPETITIVENESS ANALYSIS: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

10.1. Methodology and Key Parameters
10.2. Scoring Criteria
10.3. Overview of Peer Groups
10.4. Company Competitiveness Analysis
- 10.4.1. Competitiveness Analysis of Service Providers headquartered in North America: 2D Dot Plot
- 10.4.2. Leading Service Providers headquartered in North America: Spider Web Analysis
- 10.4.3. Competitiveness Analysis of Service Providers headquartered in Europe: 2D Dot Plot
- 10.4.4. Leading Service Providers headquartered in Europe: Spider Web Analysis
- 10.4.5. Competitiveness Analysis of Service Providers headquartered in Asia-Pacific: 2D Dot Plot
- 10.4.6. Leading Service Providers headquartered in Asia-Pacific: Spider Web Analysis

11. mRNA SYNTHESIS KITS: MARKET LANDSCAPE

11.1. Overview of mRNA Synthesis Kits
- 11.1.1. Analysis by Kit Components
- 11.1.2. Analysis by Type of Enzyme
- 11.1.3. Analysis by Type of Enzyme Mix Used
- 11.1.4. Analysis by mRNA Component Modified
- 11.1.5. Analysis by Number of Reactions
- 11.1.6. Analysis by Yield per Reaction
- 11.1.7. Analysis by Reaction Run-time
- 11.1.8. Analysis by Shelf Life
11.2. mRNA Synthesis Kits: Developers Landscape
- 11.2.1. Analysis by Year of Establishment
- 11.2.2. Analysis by Company Size
- 11.2.3. Analysis by Location of Headquarters
- 11.2.4. Most Active Players: Analysis by Number of Kits Developed

12. PRODUCT COMPETITIVENESS ANALYSIS: mRNA SYNTHESIS KITS

12.1. Methodology and Key Parameters
12.2. Scoring Criteria
12.3. Leading mRNA Synthesis Kits: 2D Dot Plot

13. COMPANY PROFILES: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

13.1. Methodology
13.2. Aldevron
- 13.2.1. Company Details
- 13.2.2. Service Portfolio
- 13.2.3. Financial Information
- 13.2.4. Future Outlook
13.3. Thermo Fischer Scientific
13.4. Revolution Biomanufacturing
13.5. BioNTech
13.6. Eurogentec
13.7. Biocell
13.8. YXgene
13.9. Aurigene Pharmaceutical Services
13.10. Biomay
13.11. GenScript
13.12. Trilink Biotechnologies

14. COMPANY PROFILES: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

14.1. Methodology
14.2. Curia
- 14.2.1. Company Details
- 14.2.2. Service Portfolio
- 14.2.3. Financial Information
- 14.2.4. Future Outlook
14.3. Lonza
14.4. Merck
14.5. Porton Advanced
14.6. Samsung Biologics
14.7. ST Pharm
14.8. Vernal Biosciences
14.9. Wuxi Biologics

15. COMPANY PROFILES: mRNA SYNTHESIS KITS

15.1. Methodology
15.2. APExBIO
- 15.2.1. Company Details
- 15.2.2. mRNA Synthesis Kits Portfolio
15.3. Biorbyt
15.4. Cell Script
15.5. Creative Biogene
15.6. Jena Bioscience
15.7. Thermo Fischer Scientific

16. PARTNERSHIPS AND COLLABORATIONS

16.1. Partnership Models
16.2. mRNA Synthesis and Manufacturing Market: Partnerships and Collaborations
- 16.2.1. Analysis by Year of Partnership
- 16.2.2. Analysis by Type of Partnership
- 16.2.3. Analysis by Year and Type of Partnership
- 16.2.4. Analysis by Type of Partner
- 16.2.5. Analysis by Type of Pharmaceutical
- 16.2.6. Analysis by Type of Drug Product
- 16.2.7. Most Active Players: Analysis by Number of Partnerships
- 16.2.8. Analysis by Geography
  - 16.2.8.1. Local and International Deals
  - 16.2.8.2. Intracontinental and Intercontinental Deals

17. LIKELY PARTNER ANALYSIS

17.1. mRNA Synthesis and Manufacturing Market: Likely Partner Analysis
17.2. Methodology and Key Parameters
17.3. Scoring Criteria
17.4. mRNA Drug Developers: Likely Partners based in North America
- 17.4.1. mRNA Drug Developers: Most Likely Partners based in North America
17.5. mRNA Drug Developers: Likely Partners based in Europe
- 17.5.1. mRNA Drug Developers: Most Likely Partners based in Europe
17.6. mRNA Drug Developers: Likely Partners based in Asia-Pacific and Rest of the World
- 17.6.1. mRNA Drug Developers: Most Likely Partners based in Asia-Pacific and Rest of the World

18. BIG PLAYER INITIATIVES

18.1. Methodology
18.2. Key Initiatives Analyzed
18.3. mRNA Synthesis and Manufacturing Market: Big Player Initiatives
- 18.3.1. Analysis by Year of Initiative
- 18.3.2. Analysis by Type of Initiative
- 18.3.3. Analysis by Year and Type of Initiative
- 18.3.4. Big Players: Analysis by Number of Initiatives
- 18.3.5. Big Players: Analysis by Type of Initiative
- 18.3.6. Analysis by Type of Pharmaceutical
- 18.3.7. Analysis by Therapeutic Area
- 18.3.8. Big Players: Analysis by Number of Partnerships
- 18.3.9. Analysis by Type of Partnership
- 18.3.10. Big Players: Analysis by Number of Expansions
- 18.3.11. Analysis by Type of Expansion
- 18.3.12. Big Players: Analysis by Region of Expansion

19. MARKET IMPACT ANALYSIS

19.1. Market Drivers
19.2. Market Restraints
19.3. Market Opportunities
19.4. Market Challenges

20. GLOBAL mRNA SYNTHESIS AND MANUFACTURING MARKET

20.1. Key Assumptions and Methodology
20.2. Global mRNA Synthesis and Manufacturing Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 20.2.1. Scenario Analysis
  - 20.2.1.1. Conservative Scenario
  - 20.2.1.2. Optimistic Scenario
20.3. Comparison with Previous Edition
20.4. Key Market Segmentations

21. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY TYPE OF PRODUCT

21.1. Methodology
21.2. mRNA Synthesis and Manufacturing Market: Distribution by Type of Product
- 21.2.1. mRNA Synthesis and Manufacturing Market for Active Pharmaceutical Ingredients: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 21.2.2. mRNA Synthesis and Manufacturing Market for Finished Dose Formulations: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

22. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Methodology
22.2. mRNA Synthesis and Manufacturing Market: Distribution by Scale of Operation
- 22.2.1. mRNA Synthesis and Manufacturing Market for Preclinical and Clinical Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 22.2.2. mRNA Synthesis and Manufacturing Market for Commercial Scale: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

23. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY SYNTHESIS AND MANUFACTURING ACTIVITY

23.1. Methodology
23.2. mRNA Synthesis and Manufacturing Market: Distribution by Synthesis and Manufacturing Activity
- 23.2.1. mRNA Synthesis and Manufacturing Market for Contract Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 23.2.2. mRNA Synthesis and Manufacturing Market for In-house Manufacturing: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

24. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY INDICATION TYPE

24.1. Methodology
24.2. mRNA Synthesis and Manufacturing Market: Distribution by Indication Type
- 24.2.1. mRNA Synthesis and Manufacturing Market for COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 24.2.2. mRNA Synthesis and Manufacturing Market for Non-COVID Indications: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

25. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY THERAPEUTIC AREA

25.1. Methodology
25.2. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area
- 25.2.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 25.2.2. mRNA Synthesis and Manufacturing Market for Oncological Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 25.2.3. mRNA Synthesis and Manufacturing Market for Other Disorders: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

26. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY APPLICATION AREA

26.1. Methodology
26.2. mRNA Synthesis and Manufacturing Market: Distribution by Application Area
- 26.2.1. mRNA Synthesis and Manufacturing Market for mRNA Vaccines: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 26.2.2. mRNA Synthesis and Manufacturing Market for mRNA Therapeutics: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

27. mRNA SYNTHESIS AND MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

27.1. Methodology
27.2. mRNA Synthesis and Manufacturing Market: Distribution by Geographical Regions
- 27.2.1. mRNA Synthesis and Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.2.1.1. mRNA Synthesis and Manufacturing Market in the US: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.2.1.2. mRNA Synthesis and Manufacturing Market in Canada: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.3.1. mRNA Synthesis and Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.1. mRNA Synthesis and Manufacturing Market in Germany: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.2. mRNA Synthesis and Manufacturing Market in France: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.3. mRNA Synthesis and Manufacturing Market in the UK: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.4. mRNA Synthesis and Manufacturing Market in Italy: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.5. mRNA Synthesis and Manufacturing Market in Spain: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.3.1.6. mRNA Synthesis and Manufacturing Market in Rest of Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.1. mRNA Synthesis and Manufacturing Market in China: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.2. mRNA Synthesis and Manufacturing Market in India: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.3. mRNA Synthesis and Manufacturing Market in Japan: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.4. mRNA Synthesis and Manufacturing Market in South Korea: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.4.1.5. mRNA Synthesis and Manufacturing Market in Rest of Asia-Pacific: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.5.1. mRNA Synthesis and Manufacturing Market in Latin America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.5.1.1. mRNA Synthesis and Manufacturing Market in Brazil: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.5.1.2. mRNA Synthesis and Manufacturing Market in Argentina: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 27.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.1. mRNA Synthesis and Manufacturing Market in Saudi Arabia: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.2. mRNA Synthesis and Manufacturing Market in Israel: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.3. mRNA Synthesis and Manufacturing Market in United Arab Emirates: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  - 27.6.1.4. mRNA Synthesis and Manufacturing Market in Rest of Middle East and North Africa: Historical Trends (since 2021) and Forecasted Estimates (till 2035)

28. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

28.1. mRNA Synthesis and Manufacturing Market in North America: Distribution by Type of Product
- 28.1.1. mRNA Synthesis and Manufacturing Market in North America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.1.2. mRNA Synthesis and Manufacturing Market in North America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.2. mRNA Synthesis and Manufacturing Market in North America: Distribution by Scale of Operation
- 28.2.1. mRNA Synthesis and Manufacturing Market in North America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.2.2. mRNA Synthesis and Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.3. mRNA Synthesis and Manufacturing Market in North America: Distribution by Synthesis and Manufacturing Activity
- 28.3.1. mRNA Synthesis and Manufacturing Market in North America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.3.2. mRNA Synthesis and Manufacturing Market in North America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.4. mRNA Synthesis and Manufacturing Market in North America: Distribution by Indication Type
- 28.4.1. mRNA Synthesis and Manufacturing Market in North America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.4.2. mRNA Synthesis and Manufacturing Market in North America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.5. mRNA Synthesis and Manufacturing Market in North America: Distribution by Therapeutic Area
- 28.5.1. mRNA Synthesis and Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.2. mRNA Synthesis and Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.5.3. mRNA Synthesis and Manufacturing Market in North America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
28.6. mRNA Synthesis and Manufacturing Market in North America: Distribution by Application Area
- 28.6.1. mRNA Synthesis and Manufacturing Market in North America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 28.6.2. mRNA Synthesis and Manufacturing Market in North America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

29. MARKET OPPORTUNITY ANALYSIS: EUROPE

29.1. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Type of Product
- 29.1.1. mRNA Synthesis and Manufacturing Market in Europe for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.1.2. mRNA Synthesis and Manufacturing Market in Europe for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.2. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Scale of Operation
- 29.2.1. mRNA Synthesis and Manufacturing Market in Europe for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.2.2. mRNA Synthesis and Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.3. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Synthesis and Manufacturing Activity
- 29.3.1. mRNA Synthesis and Manufacturing Market in Europe for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.3.2. mRNA Synthesis and Manufacturing Market in Europe for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.4. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Indication Type
- 29.4.1. mRNA Synthesis and Manufacturing Market in Europe for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.4.2. mRNA Synthesis and Manufacturing Market in Europe for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.5. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Therapeutic Area
- 29.5.1. mRNA Synthesis and Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.5.2. mRNA Synthesis and Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.5.3. mRNA Synthesis and Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
29.6. mRNA Synthesis and Manufacturing Market in Europe: Distribution by Application Area
- 29.6.1. mRNA Synthesis and Manufacturing Market in Europe for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 29.6.2. mRNA Synthesis and Manufacturing Market in Europe for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

30. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

30.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Type of Product
- 30.1.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.1.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
- 30.2.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.2.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Synthesis and Manufacturing Activity
- 30.3.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.3.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.4. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Indication Type
- 30.4.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.4.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.5. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
- 30.5.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.5.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.5.3. mRNA Synthesis and Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
30.6. mRNA Synthesis and Manufacturing Market in Asia-Pacific: Distribution by Application Area
- 30.6.1. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 30.6.2. mRNA Synthesis and Manufacturing Market in Asia-Pacific for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

31. MARKET OPPORTUNITY ANALYSIS: LATIN AMERICA

31.1. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Type of Product
- 31.1.1. mRNA Synthesis and Manufacturing Market in Latin America for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.1.2. mRNA Synthesis and Manufacturing Market in Latin America for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.2. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Scale of Operation
- 31.2.1. mRNA Synthesis and Manufacturing Market in Latin America for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.2.2. mRNA Synthesis and Manufacturing Market in Latin America for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.3. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Synthesis and Manufacturing Activity
- 31.3.1. mRNA Synthesis and Manufacturing Market in Latin America for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.3.2. mRNA Synthesis and Manufacturing Market in Latin America for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.4. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Indication Type
- 31.4.1. mRNA Synthesis and Manufacturing Market in Latin America for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.4.2. mRNA Synthesis and Manufacturing Market in Latin America for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.5. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Therapeutic Area
- 31.5.1. mRNA Synthesis and Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.5.2. mRNA Synthesis and Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.5.3. mRNA Synthesis and Manufacturing Market in Latin America for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
31.6. mRNA Synthesis and Manufacturing Market in Latin America: Distribution by Application Area
- 31.6.1. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 31.6.2. mRNA Synthesis and Manufacturing Market in Latin America for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

32. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

32.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Type of Product
- 32.1.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Active Pharmaceutical Ingredient, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.1.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Finished Dose Formulation, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
- 32.2.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Preclinical and Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.2.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Synthesis and Manufacturing Activity
- 32.3.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Contract Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.3.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for In-house Manufacturing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.4. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Indication Type
- 32.4.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.4.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for non-COVID Indications, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.5. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
- 32.5.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.5.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.5.3. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
32.6. mRNA Synthesis and Manufacturing Market in Middle East and North Africa: Distribution by Application Area
- 32.6.1. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
- 32.6.2. mRNA Synthesis and Manufacturing Market in Middle East and North Africa for mRNA Therapeutics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
*Detailed information on Chapter 28 to 32 is available in the Excel Data Packs shared along with the report**